J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Dom-meloxicam

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

91 API Suppliers, 22 USDMF, 16 CEP/COS, 8 JDMF, 16 EU WC, 32 KDMF, 21 NDC API, 36 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

50 Drugs in Development

50 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

340 FDF Dossiers, 64 FDA Orange Book, 69 Europe, 36 Canada, 34 Australia, 44 South Africa, 93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG, TABLET;ORAL - 7.5MG, SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 3 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 6 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 4 ACG Worldwide, 7 Actylis, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 20 BASF, 7 DFE Pharma, 7 Gangwal Chemicals, 2 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 Ulanqab Kema New Material, 4 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders, 40 Disintegrants & Superdisintegrants, 29 Direct Compression, 26 Granulation, 22 Thickeners and Stabilizers, 20 Lubricants & Glidants, 19 Co-Processed Excipients, 16 Coating Systems & Additives, 16 Taste Masking, 13 Chewable & Orodispersible Aids, 12 Film Formers & Plasticizers, 12 Controlled & Modified Release, 10 Solubilizers, 9 Parenteral, 8 Empty Capsules, 7 Topical, 5 Rheology Modifiers, 4 Emulsifying Agents, 3 API Stability Enhancers, 2 Coloring Agents, 1 Soft Gelatin, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 53 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 57 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

35 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

81 US Patents, 4 US Exclusivities, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 6 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/06/2025	Apex Healthcare Limited	India	Gapi Bio Co., Ltd.	20250623-148-I-717-13	Meloxicam	2025-06-23	Apex Healthcare Limited	India	Plot No. - 4710, 4711, 4707-A/8, 4707-A/9, GIDC Industrial Estate, Ankleshwar, Dist.- Bharuch - 393 002, Gujarat, India
28/06/2025	Amsa Spa	Italy	IMCD Korea Co., Ltd.	20120106-148-I-39-16(1)	Meloxicam	2012-11-09	AMSA SpA	Italy	Via G. di Vittorio, 6 22100 COMO

Dom-meloxicam

Dom-meloxicam

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

91 API Suppliers

22 USDMF

16 CEP/COS

8 JDMF

16 EU WC

32 KDMF

21 NDC API

36 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

50 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

340 FDF Dossiers

64 FDA Orange Book

69 Europe

36 Canada

34 Australia

44 South Africa

93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG

TABLET;ORAL - 7.5MG

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem

1 Evonik

3 Rochem International Inc

8 SPI Pharma

11 DKSH

6 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

4 ACG Worldwide

7 Actylis

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

20 BASF

7 DFE Pharma

7 Gangwal Chemicals

2 Ideal Cures

4 Ingredion Pharma Solutions

26 Kerry

3 Lonza Capsugel

12 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Novo Excipients

5 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

1 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

4 Silverline Chemicals

2 Ulanqab Kema New Material

4 Vasa Pharmachem

2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders

40 Disintegrants & Superdisintegrants

29 Direct Compression

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons